Virtus Biotech ETF
17 hedge funds and large institutions have $10.4M invested in Virtus Biotech ETF in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 2 closing their positions.
15% more capital invested
Capital invested by funds: $9.1M → $10.4M (+$1.35M)
2.2% more ownership
Funds ownership: 22.95% → 25.14% (+2.2%)
11% less funds holding
Funds holding: 19 → 17 (-2)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$1.17M |
| 2 |
VF
Virtu Financial
New York
|
+$583K |
| 3 |
Stifel Financial
St. Louis,
Missouri
|
+$83.6K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$58.4K |
| 5 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$48K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
-$270K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$105K |
| 3 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$40K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$12K |
| 5 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$12K |
BBP Hedge Fund Activity: Q3 2017 in Review
17 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech ETF (BBP) for Q3 2017, worth a combined $10.4M — up 15% from $9.1M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BBP and 1 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 5 added.
The largest buyer was Jane Street, adding an estimated $1.17M. The largest seller was LPL Financial, cutting an estimated $270K.
- 17 institutional investors held Virtus Biotech ETF (BBP) as of Q3 2017, down from 19 in Q2 2017.
- Funds reported $10.4M of Virtus Biotech ETF stock for Q3 2017, up 15% quarter-over-quarter.
- 1 fund opened new Virtus Biotech ETF positions in Q3 2017 and 2 closed out, a net change of -1 holder.
- The largest Virtus Biotech ETF buyer in Q3 2017 was Jane Street, an estimated $1.17M added.
- The largest Virtus Biotech ETF seller in Q3 2017 was LPL Financial, an estimated $270K sold.
Based on aggregated 13F filings for Q3 2017.